• PDB98 - TYPE 2 DIABETES- REAL-LIFE STUDY BASED ON SNIIRAM DATA OF PATIENTS INITIATING AGLP1 IN 2016

    Oct 1, 2018, 00:00

  • PIN12 - HOSPITALIZATIONS RELATED TO RESPIRATORY VIRAL INFECTIONS DURING THE 2017/18 SEASON IN THE VALENCIA REGION OF SPAIN

    Oct 1, 2018, 00:00

  • PCP64 - DEVELOPMENT AND VALIDATION OF COGNITIVE PERFORMANCE-BASED OUTCOME (PERFO) ASSESSMENTS

    Oct 1, 2018, 00:00

  • PRS101 - IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ON QUALITY OF LIFE- FINDINGS FROM A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP23 - COMPARING RISK SHARING AGREEMENTS IN CATALONIA WITH OTHERS EU COUNTRIES

    Oct 1, 2018, 00:00

  • PRS26 - THE ECONOMIC BURDEN OF ASTHMA IN ADULTS IN GREECE

    Oct 1, 2018, 00:00

  • PCN38 - NIVOLUMAB IS PREDICTED TO HAVE IMPROVED CLINICAL OUTCOMES OVER BEST SUPPORTIVE CARE IN A WESTERN POPULATION OF PRE-TREATED GASTRIC CANCER PATIENTS; AN INDIRECT TREATMENT COMPARISON ANALYSIS

    Oct 1, 2018, 00:00

  • PSY125 - PHYSICIANS' AND PHARMACISTS’ PRIORITIES IN TREATMENT DECISION-MAKING FOR CHRONIC LYMPHOCYTIC LEUKEMIA

    Oct 1, 2018, 00:00

  • PMU111 - BEST PRACTICE METHODS AND CONSIDERATIONS FOR THE DEVELOPMENT, EVALUATION, AND IMPLEMENTATION OF INTERVIEWER-ADMINISTERED PATIENT-REPORTED OUTCOMES (ADPROS)

    Oct 1, 2018, 00:00

  • PND104 - RECOMMENDATIONS FOR A NATIONAL MULTIPLE SCLEROSIS (MS) STRATEGY

    Oct 1, 2018, 00:00

  • PCV40 - BUDGET IMPACT ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

    Oct 1, 2018, 00:00

  • PSY86 - HIGHER LEVELS OF SKIN CLEARANCE ARE ASSOCIATED WITH DECREASED INDIRECT COSTS RELATED TO PRODUCTIVITY LOSS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

    Oct 1, 2018, 00:00

  • PSY208 - PATIENTS’ PREFERENCES FOR PSORIASIS TREATMENT BASED ON A DISCRETE CHOICE EXPERIMENT. COEPSO STUDY

    Oct 1, 2018, 00:00

  • PMU37 - INTRODUCTION RATE OF NEW HEMATO-ONCOLOGY DRUGS IN CATALONIA

    Oct 1, 2018, 00:00

  • PHP236 - QUALITY OF EVIDENCE ON THE COST-EFFECTIVENESS OF DRUGS PROPOSED FOR THE INCLUSION IN THE RUSSIAN VITAL AND ESSENTIAL DRUGS LIST IN 2014-2017

    Oct 1, 2018, 00:00

  • PCN59 - ASSOCIATION BETWEEN HAZARD RATIOS OF SURROGATE TIME-TO-EVENT ENDPOINTS AND OVERALL SURVIVAL IN ADVANCED/METASTATIC CANCERS

    Oct 1, 2018, 00:00

  • PMD128 - ECONOMIC AND CLINICAL OUTCOMES AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE- A RETROSPECTIVE ANALYSIS OF US HOSPITAL DATABASE

    Oct 1, 2018, 00:00

  • PRS51 - COMPARISON OF THE TREATMENT OPTIONS FOR COW'S MILK PROTEIN ALLERGY- A COST MINIMIZATION ANALYSIS BASED ON REAL WORLD CONDITIONS OF TURKEY

    Oct 1, 2018, 00:00

  • PRM228 - EXTRAPOLATION OF SURVIVAL CURVES USING EXTERNAL INFORMATION- IMPLEMENTATION OF GUYOT’S METHOD IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMS113 - TOWARD PATIENT-CENTERED VALUE ASSESSMENT- LESSONS FROM THE IVI OPEN-SOURCE VALUE PROJECT

    Oct 1, 2018, 00:00

  • PND38 - ECONOMIC IMPACT OF MULTIPLE SCLEROSIS IN PATIENTS WITH LOW PHYSICAL DISABILITY

    Oct 1, 2018, 00:00

  • PCN323 - PERJETA TREATMENT DURATION IN THE ITALIAN CLINICAL PRACTICE- A FIRST ANALYSIS OF THE AIFA PRESCRIPTION REGISTRY

    Oct 1, 2018, 00:00

  • PCN389 - QUALITY OF LIFE USING EQ-5D-3L MEASURE BEFORE ICU ADMISSION TO PREDICT THE MORTALITY OF CRITICALLY ILL CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PCV82 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE

    Oct 1, 2018, 00:00

  • CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALS

    Oct 1, 2018, 00:00

  • PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAIN

    Oct 1, 2018, 00:00

  • PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PMH67 - COMPLIANCE WITH ANTIDEPRESSANT MEDICATION IN KOREA- A CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PRS31 - THE ECONOMIC IMPACT OF OPTIMIZED POST-HOSPITALIZATION MANAGEMENT FOR AN EXACERBATION IN COPD PATIENTS IN CHINA

    Oct 1, 2018, 00:00

  • PGI16 - THE ECONOMIC BURDEN OF CHRONIC INFLAMMATORY BOWEL DISEASE PATIENTS IN FINLAND

    Oct 1, 2018, 00:00

  • PUK17 - A COST-EFFECTIVENESS ANALYSIS OF RAASI – ENABLING PATIROMER FOR THE TREATMENT OF HYPERKALEMIA IN SWEDEN

    Oct 1, 2018, 00:00

  • PMS34 - THE IMPACT OF DISEASE DURATION AND DISEASE ACTIVITY ON THE COST OF RHEUMATOID ARTHRITIS IN SPAIN- RESULTS FROM BURDEN OF RHEUMATOID ARTHRITIS ACROSS EUROPE A SOCIOECONOMIC SURVEY (BRASS)

    Oct 1, 2018, 00:00

  • PMD45 - BIOMARKER-GUIDED RISK ASSESSMENT OF ACUTE KIDNEY INJURY- RESULTS OF A COSTING MODEL FROM A UK NHS PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSY113 - ASSESSMENT OF BASIC HEALTH TECHNOLOGIES FOR ACROMEGALY PHARMACOTHERAPY IN UKRAINE

    Oct 1, 2018, 00:00

  • PMD17 - COMPARISON OF ECONOMIC AND CLINICAL OUTCOMES BETWEEN BARBED AND CONVENTIONAL SUTURES AMONG PATIENTS UNDERGOING SPINE SURGERY

    Oct 1, 2018, 00:00

  • PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS- THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTS

    Oct 1, 2018, 00:00

  • PMD138 - IMPACTS OF NEW EU MDRIVDR REGULATIONS FOR TURKEY

    Oct 1, 2018, 00:00

  • PDB116 - THE RELATIONSHIP BETWEEN POOR ADHERENCE AND HBA1C AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PRM260 - GENERATION OF RECONSTRUCTED INDIVIDUAL PATIENT DATA FROM DIGITIZED CURVES IN COST-EFFECTIVENESS MODEL- A DISCRETE OPTIMIZATION APPROACH

    Oct 1, 2018, 00:00

  • PIN86 - COST SAVINGS TO BE EXPECTED FROM THE INTRODUCTION OF NEW ANTI-HIV GENERICS IN UNIVERSITY PUBLIC HOSPITALS OF PARIS

    Oct 1, 2018, 00:00

  • PCN357 - SATISFACTION WITH HEALTH CARE IN LOCALLY ADVANCED HEAD AND NECK CANCER MEXICAN PATIENTS TREATED IN A THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PRM141 - COMPARISON OF NOVEL BAYESIAN METHODS USING EXTERNAL DATA TO IMPROVE SURVIVAL ESTIMATIONS FROM IMMATURE SURVIVAL DATA

    Oct 1, 2018, 00:00

  • PCN172 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB IN UNTREATED ALK-REARRANGED NSCLC ITALIAN PATIENTS

    Oct 1, 2018, 00:00

  • PMH50 - TREATMENT OF OPIOID USE DISORDER IN ITALY- IS THERE SCOPE FOR POLICY CHANGE?

    Oct 1, 2018, 00:00

  • PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PCV148 - A SYSTEMATIC LITERATURE REVIEW ON HEALTH STATE UTILITIES ASSOCIATED WITH NON-FATAL STROKE

    Oct 1, 2018, 00:00

  • PRM269 - SYSTEMATIC LITERATURE REVIEW (SLR) EVALUATING QUALITY ASSESSMENT TOOLS (QAT)

    Oct 1, 2018, 00:00

  • PMS111 - PATIENTS’ PREFERENCES FOR TREATMENT OF PSORIATIC ARTHRITIS BASED ON A DISCRETE CHOICE EXPERIMENT. RESULTS OF THE COEPSO STUDY

    Oct 1, 2018, 00:00

  • PSY204 - EARLY ENGAGEMENT OF THE “PATIENT VOICE” TO INFORM PATIENT REPORTED OUTCOME (PRO) MEASUREMENT IN GLOBAL PIVOTAL TREATMENT TRIAL OF CHOLANGIOCARCINOMA (CCA)

    Oct 1, 2018, 00:00

  • PND58 - COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH ABOBOTULINUMTOXINA COMPARED TO BEST SUPPORTIVE CARE IN PATIENTS WITH UPPER LIMB SPASTICITY IN SWEDEN

    Oct 1, 2018, 00:00

  • PMD12 - AMBULATORY BLOOD PRESSURE MONITORING IN THE DIAGNOSIS AND MANAGEMENT OF ARTERIAL HYPERTENSION IN CURRENT MEDICAL PRACTICE IN ALGERIA- MAPA DZ STUDY - INTERIM ANALYSIS

    Oct 1, 2018, 00:00

  • PCN292 - CANCER DRUGS IN GERMANY- HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY – AN ANALYSIS USING THE PRISMACCESS® DATABASE

    Oct 1, 2018, 00:00

  • PCN215 - EMERGING TRENDS IN THE MANAGEMENT OF NSCLC PD-L1+ PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PRS34 - COST AND DRUG UTILIZATION TRENDS IN INHALED CORTICOSTEROIDS/LONG-ACTING BETA AGONISTS (ICS/LABA) FIXED-DOSE COMBINATIONS IN SPAIN

    Oct 1, 2018, 00:00

  • PCN242 - HOW FAR DOES HIGH EXPENDITURE IMPLY EFFECTIVENESS? A STUDY OF THE RELATION BETWEEN ONCOLOGICAL DRUG EXPENDITURE AND HEALTH OUTCOMES FROM 37 COUNTRIES

    Oct 1, 2018, 00:00

  • PMD151 - SURGICAL TREATMENT, COMPLICATIONS, HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH ACROMIOCLAVICULAR DISLOCATIONS

    Oct 1, 2018, 00:00

  • PND14 - LONG-TERM EFFECTIVENESS AND CARDIOVASCULAR SAFETY OF ANTIDEMENTIA THERAPIES IN MEDICARE BENEFICIARIES NEWLY DIAGNOSED WITH ALZHEIMER’S DISEASE

    Oct 1, 2018, 00:00

  • PDB115 - IS USING MMAS-8 ALONE RELIABLE AND NONBIAS WHEN MEASURING MEDICATION ADHERENCE?

    Oct 1, 2018, 00:00

  • PRM22 - SERVICE IMPACT MODELLING AS A TOOL TO SUPPORT MARKET ACCESS FOR HEALTH TECHNOLOGY INNOVATION

    Oct 1, 2018, 00:00

  • PCV124 - HOSPITAL ADMISSIONS FOR HEART FAILURE IN ENGLAND; AN INCREASING BURDEN ON NHS RESOURCES AND THE FOCUS OF EFFECTIVE COST CONTAINMENT

    Oct 1, 2018, 00:00

  • PDB92 - PHYSICIANS’ ADHERENCE TO CLINICAL PRACTICE GUIDELINES IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS ELDERLY PATIENTS. THE IMPLICA2 STUDY

    Oct 1, 2018, 00:00

  • PCN319 - RCT NOT RWE- TWO YEAR REPORT CARD FOR THE CANCER DRUGS FUND REFORMS

    Oct 1, 2018, 00:00

  • PMS1 - COMPARATIVE EFFECTIVENESS OF BARICITINIB VERSUS SARILUMAB IN RHEUMATOID ARTHRITIS- A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PMH40 - COST-MINIMISATION ANALYSIS OF SECOND GENERATION LONG ACTING INJECTABLES (RISPERIDONE , PALIPERIDONE, AND ARIPIPRAZOLE) FOR SCHIZOPHRENIA IN SPANISH MEDIUM-LONG TERM CARE PSYCHIATRIC UNITS

    Oct 1, 2018, 00:00

  • PSS44 - AN EVALUATION OF THE CURRENT TREATMENT PATHWAYS AND ASSOCIATED NHS RESOURCE USE FOR THE MANAGEMENT OF UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS IN SECONDARY CARE

    Oct 1, 2018, 00:00

  • PCV55 - ECONOMIC BURDEN OF STROKE IN GERMANY- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMS108 - HIGH-FREQUENCY ULTRASOUND EXAMINATION OF LATERAL ANKLE LIGAMENT INJURIES IN CHILDREN

    Oct 1, 2018, 00:00

  • PND126 - SYSTEMATIC REVIEW OF THE BURDEN OF PEDIATRIC MULTIPLE SCLEROSIS IN NORTH AMERICA AND EUROPE

    Oct 1, 2018, 00:00

  • PCN71 - BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

    Oct 1, 2018, 00:00

  • PND5 - A LITERATURE REVIEW REPORTING THE SIDE EFFECTS AND ANY RELATED CONSEQUENCES CAUSED BY CURRENT CHRONIC MYASTHENIA GRAVIS TREATMENTS

    Oct 1, 2018, 00:00

  • PDB2 - COMPARISON OF ATORVASTATIN AND SIMVASTATIN EFFECT ON GLYCATED HEMOGLOBIN CONTROL AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PRS77 - SOCIOECONOMIC DETERMINANTS OF SMOKING IN GREECE

    Oct 1, 2018, 00:00

  • PND95 - THE ECONOMIC BURDEN OF NERVE RELATED INJURIES IN SPINAL CLAIMS IN THE UK

    Oct 1, 2018, 00:00

  • PHP2 - CHARACTERISTICS OF DOCTOR-SHOPPERS- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMH62 - DEPRESCRIBING OF BENZODIAZEPINES AMONGST THE PATIENTS OF DEPARTMENT OF PSYCHIATRY IN A TERTIARY CARE HOSPITAL, BANGALORE, KARNATAKA.

    Oct 1, 2018, 00:00

  • HT1 - CONSEQUENCES AND VALIDITY OF AN EMPIRICAL ESTIMATION OF THE NICE COST EFFECTIVENESS THRESHOLD

    Oct 1, 2018, 00:00

  • PRM60 - THE BURDEN OF OSTEOPOROSIS IN FOUR LATIN AMERICAN COUNTRIES- BRAZIL, MEXICO, COLOMBIA, AND ARGENTINA.

    Oct 1, 2018, 00:00

  • PRM272 - THE EUNETHTA TRANSFERABILITY TOOL- APPLICATION TO NOVEL TREATMENTS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA IN THE IRISH HEALTHCARE SETTING

    Oct 1, 2018, 00:00

  • PUK37 - USE OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) INSTRUMENTS IN CLINICAL TRIALS OF ANAEMIA OF CHRONIC KIDNEY DISEASE (CKD)

    Oct 1, 2018, 00:00

  • PHP128 - 3F - FORMULA FOR FUNDING- RETHINKING THE PORTUGUESE HOSPITAL FUNDING SYSTEM

    Oct 1, 2018, 00:00

  • PSY57 - A COMPARISON BETWEEN ON DEMAND USAGE OF RFVIIA VS PROPHYLAXIS USE OF EMICIZUMAB IN HIGH TITER INHIBITORY HEMOPHILIA A PATIENTS IN IRAN; A COST UTILITY ANALYSIS

    Oct 1, 2018, 00:00

  • PCN58 - MEDIAN SURVIVAL, MEAN SURVIVAL OR HAZARD RATIO- WHICH ENDPOINT IS THE MOST APPROPRIATE FOR PATIENTS, PHYSICIANS AND POLICY MAKERS?

    Oct 1, 2018, 00:00

  • PCV46 - PHARMACOECONOMIC EVALUATION AND BUDGET IMPACT ANALYSIS OF IVABRADINE IN CHINA

    Oct 1, 2018, 00:00

  • PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SM ...

    Oct 1, 2018, 00:00

  • PHP279 - ASSESSMENT OF THE NICE FAST-TRACK APPRAISAL (FTA) PROCESS

    Oct 1, 2018, 00:00

  • PCN251 - DESCRIPTIVE ANALYSIS OF THE USE OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKAEMIA IN EUROPE, A REAL-WORLD PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM237 - PERFORMANCE OF PROPENSITY SCORE MATCHING IN SMALL SAMPLES - SIMULATION STUDY

    Oct 1, 2018, 00:00

  • PRS11 - INITIATION OF TRIPLE THERAPY IN NEWLY DIAGNOSED COPD PATIENTS

    Oct 1, 2018, 00:00

  • PND88 - DESCRIBING REAL WORLD TREATMENT PATTERNS IN PAEDIATRIC DRAVET SYNDROME PATIENTS IN DENMARK USING ELECTRONIC MEDICAL RECORDS

    Oct 1, 2018, 00:00

  • PHP24 - ANALYSIS OF SPANISH THERAPEUTIC POSITIONING REPORTS PUBLISHED UNTIL 2017

    Oct 1, 2018, 00:00

  • PSY197 - LIMITATIONS OF THE EQ5D INSTRUMENT IN THE ASSESSMENT OF QUALITY OF LIFE IN CHRONIC RARE DISEASES – A CASE STUDY FROM FCS

    Oct 1, 2018, 00:00

  • PMU102 - A MULTIVARIATE APPROACH THAT ALLOWS COMPREHENSIVE SCORING OF MULTI-FACETED CONCEPTS- FOCUS ON MEDICINE ACCEPTABILITY IN VULNERABLE POPULATIONS

    Oct 1, 2018, 00:00

  • PHP218 - HOW HIGH CAN YOU GO? - THE IMPACT OF INDICATION EXPANSION AND MARKET COMPETITION ON DRUG PRICES IN THE EU5

    Oct 1, 2018, 00:00

  • PMS21 - BUDGET IMPACT MODEL OF INCLUSION OF TOFACITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN FRANCE

    Oct 1, 2018, 00:00

  • PCN46 - DURABLE THERAPY IN FRONTLINE CLL IMPROVES OS

    Oct 1, 2018, 00:00

  • PMU14 - COMPARISON TO STANDARD OF CARE- MODELISATION OF POTENTIAL SELECTION BIAS FOR ACTIVE REFERENCE IN RANDOMISED CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PCN157 - COST-EFFECTIVENESS ANALYSIS OF THE USE OF COLONOSCOPY AS A SCREENING METHOD FOR COLON CANCER IN PATIENTS OVER 50 YEARS OF AGE ON MANDATORY HEALTH INSURANCE

    Oct 1, 2018, 00:00

  • ND4 - COST-EFFECTIVENESS EVALUATION OF THE INTRA-DUODENAL CONTINUOUS LEVODOPA INFUSION IN ADVANCED AND SEVERE PARKINSON’S DISEASE

    Oct 1, 2018, 00:00

  • PMS120 - THE IMPACT OF RHEUMATOID ARTHRITIS (RA) ON A PATIENT’S ABILITY TO WORK AND EARLY RETIREMENT DUE TO RA

    Oct 1, 2018, 00:00

  • PCN30 - EVIDENCE GENERATION IN A EARLY ACCESS STRATEGY FOR TARGETED ONCOLOGY THERAPIES- A COMPARISON IN NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PSY16 - HEALTH OUTCOME IMPROVEMENTS IN SPINAL MUSCULAR ATROPHY TYPE 1 PATIENTS WITH AVXS-101 GENE REPLACEMENT THERAPY

    Oct 1, 2018, 00:00

  • PCN158 - THE ADDED VALUE OF PERSONALIZED FOLLOW-UP FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

    Oct 1, 2018, 00:00

  • PUK22 - ESTIMATES OF KIDNEY STONES COSTS. AN ANALYSIS OF CLINICAL AND ADMINISTRATIVE DATA TO MEASURE THE BURDEN OF KIDNEY STONES IN ITALY

    Oct 1, 2018, 00:00

  • PCP69 - APPLICATION DECREE OF JARDE LAW- EXPERIENCE FROM A NON-INTERVENTIONAL STUDY IN FRANCE

    Oct 1, 2018, 00:00

  • PCV42 - A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PMH76 - PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

    Oct 1, 2018, 00:00

  • PMD3 - METHODS FOR QUANTIFYING POSTERIOR CAPSULAR OPACIFICATION AND THE IMPACT OF INTRAOCULAR LENS MATERIAL ON SEVERITY SCORES - A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PIN46 - COST-EFFECTIVENESS COMPARISON OF BALOXAVIR MARBOXIL AND LANINAMIVIR FOR THE TREATMENT OF INFLUENZA IN JAPAN

    Oct 1, 2018, 00:00

  • PHP191 - EVALUATION OF THE RENEWED LIFE REFORM PROGRAM FOR WORKERS WITH PREMORBID METABOLIC SYNDROME, OVERWEIGHT AND OBESITY IN THE AMAZONAS ASSISTANCE NETWORK OF PERUVIAN SOCIAL SECURITY

    Oct 1, 2018, 00:00

  • PMD123 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN ELECTIVE HIP AND KNEE SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN165 - COST-EFFECTIVENESS OF SORAFENIB FOR METASTATIC RENAL CELL CARCINOMA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PRM222 - STUDY OF THE SEVERITY OF VASO-OCCLUSIVE CRISIS FOR PATIENT SUFFERING FROM SICKLE CELL DISEASE IN FRANCE USING A MACHINE LEARNING APPROACH ON THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • PSY183 - SCOPE REVIEW OF ORPHAN DRUG PUBLIC POLICIES AND LEGISLATION IN LATIN AMERICA

    Oct 1, 2018, 00:00

  • PND26 - COST IMPLICATIONS OF A NOVEL WEIGHT DOSED TREATMENT FOR HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PRM167 - MAPPING THE SF-36 TO EQ-5D-3L IN RANDOMIZED TRIAL- THE EMOCAR STUDY (MAY 2011 – APRIL 2016)

    Oct 1, 2018, 00:00

  • PRM182 - CULTURAL ADAPTATION AND LOCALISATION OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) INTO ARABIC VARIANTS TO ENSURE CULTURAL SUITABILITY.

    Oct 1, 2018, 00:00

  • PRM181 - USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE FOR A SYSTEMATIC LITERATURE REVIEW OF UTILITIES IN INFECTIOUS DISEASE

    Oct 1, 2018, 00:00

  • PRS37 - ECONOMIC BURDEN ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN329 - OUTCOMES-BASED ARRANGEMENTS IN ONCOLOGY- A LANDSCAPE ANALYSIS

    Oct 1, 2018, 00:00

  • PSS70 - ACNE AND ABSENTEEISM- RESULTS OF A REAL-LIFE STUDY

    Oct 1, 2018, 00:00

  • PRM93 - SNDS, THE FRENCH NATIONWIDE CLAIMS DATABASE- A POWERFUL TOOL FOR PHARMACOECONOMY AND PHARMACOEPIDEMIOLOGY

    Oct 1, 2018, 00:00

  • PHP130 - SICK-PAY EXPENDITURES IN HUNGARY BETWEEN 2005-2016

    Oct 1, 2018, 00:00

  • PMU69 - DESCRIPTION OF HEALTH CARE ACTIVITY OF A NUTRITION AREA MANAGED BY A HOSPITAL PHARMACY SERVICE

    Oct 1, 2018, 00:00

  • PCN317 - THE CANCER DRUGS FUND- KEY UNCERTAINTIES, DATA COLLECTION PLANS, ANALYTICAL METHODS AND USE OF THE SYSTEMATIC ANTI-CANCER THERAPY (SACT) REAL WORLD DATA SET

    Oct 1, 2018, 00:00

  • PHP313 - ANALYSIS OF THE ANALYTICAL AND METHODOLOGICAL FRAMEWORK OF THE HEALTH ECONOMIC EVALUATION ASSESSMENTS DELIVERED IN FRANCE

    Oct 1, 2018, 00:00

  • PRM27 - PREDICTING STABILITY OUTCOMES FOR FOSTERED CHILDREN USING MACHINE LEARNING- APPLICATION OF OUTCOME RESEARCH TO SOCIAL CARE

    Oct 1, 2018, 00:00

  • PDB120 - EVALUATION OF HEALTH STATUS OF TYPE 2 DIABETES OUTPATIENTS RECEIVING CARE IN A TERTIARY HOSPITAL IN NIGERIA

    Oct 1, 2018, 00:00

  • PMD165 - EVALUATING DIGITAL HEALTH TECHNOLOGIES- A REVIEW OF HTA GUIDANCE AND ASSESSMENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PDB50 - COST OF HYPOGLYCAEMIA IN BOSNIA AND HERZEGOVINA

    Oct 1, 2018, 00:00

  • PRM82 - REAL WORLD EVIDENCE (RWE) FROM ITALIAN NHS-AIFA REGISTRIES

    Oct 1, 2018, 00:00

  • PND48 - HEALTH AND ECONOMIC BURDEN OF PARKINSON’S DISEASE IN FINLAND

    Oct 1, 2018, 00:00

  • PRS71 - WASTEFUL HEALTHCARE SPENDING ON MEDICATION OVERSUPPLY IN ROUTINE USES OF COMBINED INHALED CORTICOSTEROID AND LONG-ACTING BETA2-AGONISTS (ICS/LABA) INHALERS

    Oct 1, 2018, 00:00

  • PMU39 - PRICE ASSESSMENT OF ESSENTIAL GENERICS IN THE CITY OF YEREVAN

    Oct 1, 2018, 00:00

  • PCV61 - PRODUCTIVITY LOSS AND LOCAL INDIRECT COSTS ASSOCIATED WITH ACUTE CORONARY SYNDROME AND STROKE IN SPAIN

    Oct 1, 2018, 00:00

  • PHP320 - ANALYSIS OF HTA PROCESS ON THE BASIS OF PHARMACOECONOMIC GUIDELINES IN CENTRAL EASTERN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PMD164 - THE MANAGEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS (T2)- THE ROLE OF GLYCATED ALBUMIN

    Oct 1, 2018, 00:00

  • PDB83 - A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN NON-INSULIN ANTIDIABETIC TREATMENTS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PCN86 - VALIDATION OF THE IMPACT OF TREATMENT EVOLUTION IN NON-SMALL CELL LUNG CANCER (NSCLC) MODEL (ITEN)- A DISCRETE EVENT PATIENT SIMULATION

    Oct 1, 2018, 00:00

  • PSY167 - COMPARISON OF PHARMACOECONOMIC (PE) EVALUATIONS FOR DRUGS FOR RARE DISEASES (DRDS) EVALUATED BY CADTH AND NICE.

    Oct 1, 2018, 00:00

  • PRM44 - DIFFERENTIATING DISCOUNT RATES IN COST-EFFECTIVENESS EVALUATIONS IN THE CONTEXT OF GENE THERAPIES.

    Oct 1, 2018, 00:00

  • MD3 - FROM DRUG-DELIVERY DEVICE TO DISEASE MANAGEMENT TOOL- A STUDY OF PATIENT PREFERENCES FOR ENHANCED FEATURES IN NEXT GENERATION SELF-INJECTION DEVICES

    Oct 1, 2018, 00:00

  • PMU62 - ECONOMIC EVALUATION OF MESALAZINE 4G (SALOFALK®) IN THE TREATMENT OF PATIENTS WITH ULCERATIVE COLITIS LOCATED IN THE RECTUM AND SIGMOID

    Oct 1, 2018, 00:00

  • PSY2 - IDENTIFICATION OF POTENTIAL BIAS FROM DATA SOURCES AND STUDY DESIGNS USED TO ESTIMATE PLATELET TRANSFUSION ADVERSE EVENT RATES

    Oct 1, 2018, 00:00

  • PRS82 - TREND AND FACTORS ASSOCIATED WITH PREVENTABLE HOSPITALIZATION AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS- A DECADE EXPERIENCE OF A NATIONAL HEALTH INSURANCE PROGRAM

    Oct 1, 2018, 00:00

  • PDB48 - ANNUAL COST OF ILLNESS OF ISCHEMIC STROKE IN TYPE 2 DIABETIC PATIENTS IN TURKEY

    Oct 1, 2018, 00:00

  • PRM185 - COMPARISON OF THE MEASUREMENT PROPERTIES OF THE EQ-5D-5L AND EQ-5D-3L IN PATIENTS WITH CROHN’S DISEASE

    Oct 1, 2018, 00:00

  • PIN54 - COST-EFFECTIVENESS OF INTRODUCING MEN VACCINATION AGAINST HUMAN PAPILLOMAVIRUS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PCN190 - COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PRS76 - DISEASE ADAPTATION AND PERCEIVED HEALTH STATUS- DOES IT EXIST AND CAN IT BE QUANTIFIED? INVESTIGATING EQ-5D IN SEVERE ASTHMA

    Oct 1, 2018, 00:00

  • PMU24 - WHICH MODEL(S) ARE USED TO ASSESS INDIVIDUAL-LEVEL SURROGACY IN ONCOLOGY USING KENDALL’S TAU? A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PIN113 - ASSESSMENT OF THE EFFICACY AND SAFETY OF ANIDULAFUNGIN, COMPARED WITH OTHER AVAILABLE ANTIFUNGALTHERAPIES TO TREAT INVASIVE CANDIDIASIS- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP210 - DEVELOPMENT OF DRUG INNOVATIVNESS ASSESSMENT TOOL FOR DECISION-MAKING IN REIMBURSEMENT AND PRICING

    Oct 1, 2018, 00:00

  • PSY166 - MARKET ACCESS TRENDS FOR ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS) IN EUROPE

    Oct 1, 2018, 00:00

  • PHP221 - CONDITIONAL APPROVAL- ARE PAYERS REWARDING THESE HIGHLY NEEDED PHARMACEUTICALS?

    Oct 1, 2018, 00:00

  • PDB28 - TYPE 2 DIABETES- CHANGING PATTERNS OF USE OF THE VARIOUS CLASSES OF ANTIDIABETIC DRUGS 8 YEARS AFTER STARTING TREATMENT- A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)

    Oct 1, 2018, 00:00

  • PHP204 - VALIDATION OF A MULTICRITERIA DECISION ANALYSIS (MCDA) FRAMEWORK TO INCORPORATE THE PATIENTS’ PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PHP294 - A REVIEW OF RECENT APPRAISALS FROM THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW- HOW IMPORTANT IS THE ICER?

    Oct 1, 2018, 00:00

  • PCN3 - REAL WORLD EVIDENCE OF METASTATIC BREAST CANCER TREATMENT- A COMPARISON OF ADVERSE EFFECTS BETWEEN PALBOCICLIB TREATMENT AND ENDOCRINE THERAPY

    Oct 1, 2018, 00:00

  • PIH32 - INNOVATIVE PAYMENT MECHANISM- SOLVING INEQUITIES FOR HER2 (-) BREAST CANCER CASES IN CHILE.

    Oct 1, 2018, 00:00

  • PMS73 - BRIGHT FUTURE FOR THE USE OF BIOSIMILAR INFLIXIMAB- EVIDENCE-BASED ANALYSIS USING HEALTHCARE CLAIM DATABASE

    Oct 1, 2018, 00:00

  • PCV109 - ARE CARDIOVASCULAR MEDICINES IN QATAR AND LEBANON AFFORDABLE? AN ANALYSIS AND COMPARISON OF TWO DEVELOPING MIDDLE-EASTERN COUNTRIES

    Oct 1, 2018, 00:00

  • PMU78 - MEDICATION THERAPY MANAGEMENT WITH DIRECT PATIENT ENGAGEMENT TO ADDRESS NON-ADHERENCE TO SPECIALTY DRUGS

    Oct 1, 2018, 00:00

  • PND123 - PATIENT AND CAREGIVER WEB-BASED SURVEY- HEALTH UTILITIES IN TUBEROUS SCLEROSIS COMPLEX (TSC) PATIENT POPULATION

    Oct 1, 2018, 00:00

  • PCN366 - QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN

    Oct 1, 2018, 00:00

  • PSY220 - IMPACT OF KERATOCONUS AND ITS TREATMENTS ON PATIENTS’ DAILY LIFE- QUALITATIVE PHASE OF THE DEVELOPMENT OF A QUALITY OF LIFE QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PCN4 - EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PMU46 - IN-HOSPITAL ECONOMIC BURDEN OF ANASTOMOTIC LEAKAGE AFTER COLORECTAL ANASTOMOSIS SURGERY- A REAL-WORLD COST ANALYSIS

    Oct 1, 2018, 00:00

  • PCN63 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING MATCHING-ADJUSTED INDIRECT COMPARISONS AND SIMULATED TREATMENT COMPARISONS

    Oct 1, 2018, 00:00

  • PGI8 - SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF LINACLOTIDE VERSUS OTHER ORAL CONSTIPATION TREATMENTS IN PATIENTS WITH CHRONIC CONSTIPATION

    Oct 1, 2018, 00:00

  • PIN107 - BACTERIAL SKIN AND SOFT TISSUE INFECTIONS- GLOBAL MAPPING BY GEOGRAPHICAL DISTRIBUTION AND CLIMATE AREA

    Oct 1, 2018, 00:00

  • PND31 - COST ANALYSIS OF BOTULINUM TOXIN A (BOTOX® AND XEOMIN®) IN REAL-WORLD CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACY

    Oct 1, 2018, 00:00

  • PSS27 - A COST-EFFECTIVENESS ANALYSIS OF TWO VISUAL ACUITY CUTOFFS FOR CATARACT SURGERY IN PATIENTS WITH PSEUDOEXFOLIATION IN UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PCV76 - COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

    Oct 1, 2018, 00:00

  • PSY111 - PHARMACOECONOMIC EVALUATION OF BIOSIMILAR RECOMBINANT ALPHA-EPOETIN IN THE TREATMENT OF ANEMIA IN HEMODIALYSIS PATIENTS

    Oct 1, 2018, 00:00

  • PDB105 - INCREASED BURDEN OF MULTIMORBIDITY AMONGST DIABETES PATIENTS- A MULTINATIONAL SURVEY

    Oct 1, 2018, 00:00

  • PRS15 - A 10-YEAR FOLLOW-UP OF A COHORT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) THROUGH A ONE-WAY MARKOV MODEL

    Oct 1, 2018, 00:00

  • PIN123 - USING EQ-5D TO MEASURE QUALITY OF LIFE IN PATIENTS WITH DIABETIC FOOT ULCERS AND VENOUS LEG ULCERS

    Oct 1, 2018, 00:00

  • PMD111 - THE COST-EFFECTIVENESS OF BIMODAL AIDING COMPARED TO UNILATERAL AND BILATERAL COCHLEAR IMPLANT USE IN ADULTS WITH BILATERAL SEVERE TO PROFOUND DEAFNESS

    Oct 1, 2018, 00:00

  • PMD13 - PREVALENCE OF ISOLATED HYPERTENSION AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PMU28 - A CROSS INDICATION BUDGET IMPACT ANALYSIS OF SECUKINUMAB- A GREEK PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMD125 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN FRAGILITY FRACTURE SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMD97 - TECHNOLOGICAL-ECONOMIC COMPARISON OF ENDODONTICS TECHNIQUE WITH FOCUS ON NIKL-TITAN SYSTEMS

    Oct 1, 2018, 00:00

  • PDB131 - LATENT CLASS ANALYSIS FOR PERSONALIZED DIABETES MANAGEMENT- ONE SIZE DOES NOT FIT ALL?

    Oct 1, 2018, 00:00

  • PRM69 - AN INCREASE OVER TIME IN PUBLISHED REAL-WORLD AND HEALTH ECONOMIC EVIDENCE IN CLINICAL JOURNALS ACROSS LYSOSOMAL STORAGE DISORDERS

    Oct 1, 2018, 00:00

  • PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK

    Oct 1, 2018, 00:00

  • PMD76 - WHICH INTENSIVE CARE ANALYTICS ARE A WORTHWHILE INVESTMENT FOR DEVELOPERS? AN EARLY HEALTH TECHNOLOGY ASSESSMENT.

    Oct 1, 2018, 00:00

  • PHP298 - ON THE RIGHT TRACK? EXAMINING NICE’S FAST-TRACK APPRAISAL PROCESS

    Oct 1, 2018, 00:00

  • PHP155 - THE DEVELOPMENT AND EMPIRICAL APPLICATION OF A MULTIPLE SOCIETAL VALUE CRITERIA APPROACH TO RESOURCE ALLOCATION AMONG DISEASE CATEGORIES

    Oct 1, 2018, 00:00

  • PSY122 - MANAGEMENT OF POOR PROGNOSIS MULTIPLE MYELOMA PATIENTS UNDER REGULAR CLINICAL CONDITIONS IN SPAIN

    Oct 1, 2018, 00:00

  • PND64 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS FOR TREATMENT OF RRMS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PMS41 - COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN GREECE

    Oct 1, 2018, 00:00

  • PHP308 - CONSIDERATION OF LEGAL ASPECTS IN HTA – CAN A SYSTEMATIC AND PRAGMATIC METHODOLOGICAL APPROACH BE IDENTIFIED IN GERMAN HTA?

    Oct 1, 2018, 00:00

  • PDB10 - MACROVASCULAR AND MICROVASCULAR COMPLICATIONS OF TYPE 2 DIABETES MELLITUS AND ITS ASSOCIATED FREQUENCY OF HOSPITAL ADMISSION

    Oct 1, 2018, 00:00

  • PSY82 - ANNUAL COST OF CLOTTING FACTORS IN PATIENTS WITH SEVERE (SEV) HEMOPHILIA A (HA) IN FRANCE

    Oct 1, 2018, 00:00

  • PMS23 - OPTIMIZING TREATMENT FOR RHEUMATOID ARTHRITIS IN THE KINGDOM OF SAUDI ARABIA (OPTRA)

    Oct 1, 2018, 00:00

  • PND135 - FATIGUE IN MULTIPLE SCLEROSIS- ASSESSING THE PSYCHOMETRIC PROPERTIES OF THE MFIS-5 QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PIN77 - DELAY BETWEEN HIV DIAGNOSIS AND TREATMENT INITIATION ACROSS THE EU5

    Oct 1, 2018, 00:00

  • PCP26 - THE EUNETHTA COMPANION GUIDE – A REPOSITORY TO STRENGTHEN THE QUALITY OF EUNETHTA’S JOINT HTA PRODUCTION

    Oct 1, 2018, 00:00

  • PCN371 - HEALTH RELATED QUALITY OF LIFE IN CERVIX-UTERI CANCER WOMEN TREATED IN A MEXICAN THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PHP147 - CHANGES IN THE NUMBER OF PHYSICIANS IN THE HEALTH CARE SYSTEM OF EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PCN182 - COST-EFFECTIVENESS RANDOMIZED STUDY OF LAPAROSCOPIC VERSUS OPEN BILATERAL INGUINAL HERNIA REPAIR

    Oct 1, 2018, 00:00

  • PMS28 - SECUKINUMAB VERSUS INFLIXIMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS- A COST PER RESPONDER ANALYSIS AMONG 48 WEEKS FROM A TUNISIAN PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PMH77 - ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BY THE SF36V2 IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

    Oct 1, 2018, 00:00

  • PHP142 - SEVERITY ADJUSTED PROBABILITY OF BEING COST-EFFECTIVE- A NOVEL APPROACH TO INTEGRATE SEVERITY AND COST-EFFECTIVENESS WITH APPLICATIONS TO NORWAY AND THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PMD133 - SUCCESS FACTORS FOR §137H SGB V ASSESSMENT OF MEDICAL DEVICES IN GERMANY

    Oct 1, 2018, 00:00

  • PHP167 - COUNTRY-LEVEL COST-EFFECTIVENESS THRESHOLD- INITIAL ESTIMATES IN REPUBLIC OF BELARUS

    Oct 1, 2018, 00:00

  • PCV51 - COST ANALYSIS OF SAFETY OUTCOMES OF DABIGATRAN VS. WARFARIN IN THE SPANISH NATIONAL HEALTH SERVICE

    Oct 1, 2018, 00:00

  • PP3 - TUNING INTO WHAT PATIENTS SAY ABOUT CLINICAL TRIALS WHEN SCIENTISTS AND CLINICIANS ARE NOT LISTENING- IMPLICATIONS FOR RECRUITMENT

    Oct 1, 2018, 00:00

  • PCN355 - UTILITY IN FRENCH HEALTH-ECONOMIC OPINIONS- KEY LEARNINGS OF A RETROSPECTIVE ANALYSIS IN ONCOLOGY DRUGS

    Oct 1, 2018, 00:00

  • PSS24 - ESTIMATION OF THE LONG-TERM POPULATION COSTS AND BENEFITS FOR FIVE DIFFERENT VARICELLA CHILDHOOD IMMUNIZATION STRATEGIES IN BULGARIA

    Oct 1, 2018, 00:00

  • Association between Higher Generic Drug Use and Medicare Part D Star Ratings- An Observational Analysis

    Oct 1, 2018, 00:00

  • HT2 - PATIENT CENTRIC MEASURES IN HTAS FOR AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PGI6 - 30-DAY MORTALITY RATES FOLLOWING HOSPITAL ADMISSION FOR ULCERATIVE COLITIS AND CLOSTRIDIUM DIFFICILE INFECTION

    Oct 1, 2018, 00:00

  • PCN148 - COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO TREATMENT OPTIONS FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY - UPDATED RESULTS

    Oct 1, 2018, 00:00

  • PDB80 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER METHODS QUESTIONS ITS CONCLUSIONS

    Oct 1, 2018, 00:00

  • PMS92 - THE CORRELATION BETWEEN MENTAL DISORDER PARAMETERS AND MEDICAL ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Oct 1, 2018, 00:00

  • PMD80 - IS SCREENING FOR OVARIAN CANCER EFFECTIVE AND COST EFFECTIVE IN AUSTRIA? A MODEL-BASED ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PND32 - COST COMPARISON OF MULTIPLE SCLEROSIS FIRST LINE TREATMENT WITH AVAILABLE INTERFERONS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PCN183 - ROBOTIC VERSUS LAPAROSCOPIC SURGERY FOR RECTAL CANCER- A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESS

    Oct 1, 2018, 00:00

  • PSY170 - IMPACT OF MULTIPLE INDICATIONS ON PRICE AND ACCESS OF DRUGS FOR AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PHP302 - HOW AFFORDABILITY IS CONSIDERED FOR PRICING POLICIES?

    Oct 1, 2018, 00:00

  • PHP33 - UNDERSTANDING THE JAPANESE POLICY INITIATIVES AND THE PATIENT CHARACTERISTICS OF RARE, INTRACTABLE DISEASES

    Oct 1, 2018, 00:00

  • PND138 - INFORMATION SEARCHING PREFERENCES IN PEOPLE WITH MULTIPLE SCLEROSIS- THE INFOSEEK STUDY

    Oct 1, 2018, 00:00

  • PMU118 - COGNITIVE DEBRIEFING INTERVIEW STUDIES TO INFORM PATIENT-REPORTED OUTCOME QUESTIONNAIRE DEVELOPMENT- A LITERATURE REVIEW AND SUGGESTED REPORTING GUIDELINES

    Oct 1, 2018, 00:00

  • PHP173 - PHARMACEUTICAL PROCUREMENT IN UKRAINE- AN ANALYSIS OF NEW TRENDS IN IMPROVING ACCESS TO MEDICINES

    Oct 1, 2018, 00:00

  • PSY120 - ECONOMIC BURDEN OF SYMPTOMATIC MULTIPLE MYELOMA ON THE ITALIAN HEALTH CARE SYSTEM- FOCUS ON THE MAIN DRIVER COSTS.

    Oct 1, 2018, 00:00

  • PGI46 - PSYCHOMETRIC EVALUATION OF THE DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-CONSTIPATION (DIBSS-C)

    Oct 1, 2018, 00:00

  • PMH75 - PATIENT-REPORTED OUTCOMES IN PATIENTS WITH DEPRESSION- A QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA

    Oct 1, 2018, 00:00

  • PMU50 - COSTS OF NEUROMONITORING - EXAMINING THE POST-OPERATIVE FINANCIAL BURDEN TO PATIENTS FOLLOWING SPINAL SURGERY

    Oct 1, 2018, 00:00

  • PDB54 - ESTIMATED EVENTS AVOIDED AND COST OFFSETS ASSOCIATED WITH USING CANAGLIFLOZIN TO TREAT PATIENTS WITH TYPE TWO DIABETES MELLITUS (T2DM) WITH OR AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE (CVD) IN ENGLAND

    Oct 1, 2018, 00:00

  • PHP99 - OVER-THE-COUNTER MEDICINES USE AND ITS ASSOCIATION WITH RISK PERCEPTION AND SAFETY AMONG WOMEN VISITING COMMUNITY PHARMACIES IN MALAYSIA

    Oct 1, 2018, 00:00

  • PMH19 - BUDGET IMPACT ANALYSIS OF INHALED LOXAPINE FOR THE MANAGEMENT OF PSYCHOMOTOR AGITATION IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER IN ITALY

    Oct 1, 2018, 00:00

  • PRM103 - SECONDARY USE OF EXISTING PERSONAL HEALTH DATA FOR NON-INTERVENTIONAL STUDIES IN FRANCE

    Oct 1, 2018, 00:00

  • PRM213 - LEARNINGS FROM CONSUMER RESEARCH FOR PATIENT PREFERENCE RESEARCH

    Oct 1, 2018, 00:00

  • PCV144 - EFFECT OF CONVENIENCE OF ORAL ANTICOAGULANT THERAPY ON MEDICATION ADHERENCE- RESULTS OF AN INTERNATIONAL STATED PREFERENCE SURVEY

    Oct 1, 2018, 00:00

  • PMS24 - COST MINIMIZATION ANALYSIS OF THIRD LINE RHEUMATOID ARTHRITIS DRUGS IN ECUADOR

    Oct 1, 2018, 00:00

  • PDB72 - PLATELET-RICH PLASMA IN DIABETIC FOOT ULCERS- COST-EFFECTIVENESS ANALYSIS FOR SPAIN

    Oct 1, 2018, 00:00

  • PRM130 - OPEN-SOURCE SOFTWARE FOR DEVELOPING COMPUTATIONALLY EFFICIENT COST-EFFECTIVENESS MODELS TO EVALUATE SEQUENTIAL TREATMENT STRATEGIES IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PCP23 - DOES THE EUROPEAN UNION (EU) NEED EUROPEAN HTA OR EUROPEAN PROCUREMENT?

    Oct 1, 2018, 00:00

  • PRM270 - IMPACT OF THE CLINICAL TRIAL DESIGN STRATEGY ON PRODUCT MARKET UPTAKE AND OVERALL COMMERCIAL SUCCESS

    Oct 1, 2018, 00:00

  • PIN122 - INVESTIGATION OF FACILITATING FACTORS OF PARENTS’ DECISION-MAKING IN VACCINATION

    Oct 1, 2018, 00:00

  • PUK25 - EVALUATION OF THE RECOMMENDATIONS COMPLIANCE ON THE DIABETIC NEPHROPATHY MANAGEMENT IN FRANCE- THE ND-CRIS COHORT (2012-2017)

    Oct 1, 2018, 00:00

  • PHP16 - CHANGE IN THE QUANTITY OF ONE-DAY SURGERY INTERVENTIONS BETWEEN 1997-2017 IN HUNGARY

    Oct 1, 2018, 00:00

  • PCN12 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN WESTERN EUROPE

    Oct 1, 2018, 00:00

  • PCV100 - ANALYSIS OF DEMOGRAPHY DATA OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO TYPE OF INSTITUTE IN HUNGARY

    Oct 1, 2018, 00:00

  • PRS87 - COMPARABILITY OF A PROVISIONED DEVICE VERSUS BRING YOUR OWN DEVICE FOR COMPLETION OF PATIENT-REPORTED OUTCOME (PRO) MEASURES BY PARTICIPANTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- QUALITATIVE INTERVIEW FINDINGS

    Oct 1, 2018, 00:00

  • PRM238 - A SIMULATION STUDY ASSESSING THE USE OF PLAUSIBLY VAGUE PRIOR DISTRIBUTIONS IN A BAYESIAN META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP300 - HEALTH TECHNOLOGY ASSESSMENT ROADMAP FOR UKRAINE - THE PERSPECTIVE OF STAKHOLDERS ON CURRENT STATUS AND FUTURE OPPORTUNITIES

    Oct 1, 2018, 00:00

  • PRM273 - METHODOLOGICAL CONSIDERATIONS ON THE RECOMMENDATIONS TO CONDUCT AND REPORT SYSTEMATIC REVIEWS IN MEDICAL LITERATURE- SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PND130 - MEASURING WHAT MATTERS TO PEOPLE WITH MULTIPLE SCLEROSIS AND PREFERENCES FOR NOVEL METHODS TO ASSESS CLINICAL OUTCOMES

    Oct 1, 2018, 00:00

  • PSY218 - SYMPTOM AND IMPACT DISTURBANCE- FINDINGS FROM A QUALITATIVE ASSESSMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

    Oct 1, 2018, 00:00

  • PMD40 - THE BUDGET IMPACT AND COST-CONSEQUENCE OF TREATING LEG ULCERS WITH URGOSTART

    Oct 1, 2018, 00:00

  • PMD62 - ADVANCEMENT IN SELF-MONITORING OF BLOOD GLUCOSE (SMBG) TECHNOLOGY IMPROVES METABOLIC CONTROL, DIABETES MANAGEMENT AND PATIENT SATISFACTION IN PATIENTS WITH DIABETES AND HAS THE POTENTIAL FOR SUBSTANTIAL COST SAVINGS FOR THE GERMAN H ...

    Oct 1, 2018, 00:00

  • PDB49 - TYPE 2 DIABETES MELLITUS IN ALGERIA – A COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PHP169 - MCDA EVIDEM REFERENCE VALUE FRAMEWORK FOR DRUG EVALUATION AND DECISION MAKING IN SPAIN

    Oct 1, 2018, 00:00

  • PHP160 - PRESCRIPTION CHARGES IN SCOTLAND- THE IMPACT OF FREE PRESCRIPTIONS

    Oct 1, 2018, 00:00

  • PHP111 - EXPLORING THE LEVELS OF UNDERSTANDING OF PERSONALIZED MEDICINE AMONGST MEDICAL STUDENTS IN SARAJEVO

    Oct 1, 2018, 00:00

  • HT8 - DOES IQWIG MATTER? FREQUENCY OF DIVERGENT OPINIONS BETWEEN IQWIG AND THE G-BA

    Oct 1, 2018, 00:00

  • PCN224 - TOWARDS CLINICAL ADOPTION OF REPURPOSED DRUGS IN ONCOLOGY- OVERCOMING REGULATORY AND MARKET ACCESS BARRIERS IN EUROPE

    Oct 1, 2018, 00:00

  • PHP103 - OUT-OF-POCKET EXPENDITURE FOR PRESCRIBED AND OVER-THE-COUNTER MEDICATIONS IN GREECE

    Oct 1, 2018, 00:00

  • PHP8 - THE ROLE OF GENERAL PRACTITIONERS IN TRAUMA CARE- VARIATION BY INJURY TYPE, REGION, PATIENT PROFILE, AND OVER TIME

    Oct 1, 2018, 00:00

  • PMD47 - BUDGET IMPACT MODELLING OF POINT-OF-CARE HBA1C MONITORING OF PATIENTS WITH DIABETES MELLITUS TYPE II IN THE UNITED KINGDOM AND AUSTRALIA

    Oct 1, 2018, 00:00

  • PSY150 - INEQUITY OF ORPHAN DRUGS PRICES IN EUROPE

    Oct 1, 2018, 00:00

  • PMS31 - SECUKINUMAB AS A MORE EEFICIENT ALTERNATIVE FOR ANKYLOSING SPONDYLITIS TREATMENT- A COST PER RESPONDER ANALYSIS FROM KOREAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSY52 - ECONOMIC IMPACT OF IMPROVING PATIENT SAFETY USING SUGAMMADEX FOR ROUTINE REVERSAL OF NEUROMUSCULAR BLOCKADE IN SPAIN

    Oct 1, 2018, 00:00

  • PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMEN

    Oct 1, 2018, 00:00

  • PDB73 - INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICE

    Oct 1, 2018, 00:00

  • PSY41 - OVERALL SURVIVAL AND NON-RELAPSE MORTALITY OF PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PSY133 - LIVES SAVED FROM REDUCTIONS IN CO-PRESCRIBING OF OPIOIDS AND BENZODIAZEPINES

    Oct 1, 2018, 00:00

  • PDB91 - EXPLAINING THE DISPARITIES OF MARKET ACCESS FOR GLIFLOZINS IN FRANCE, SPAIN, GERMANY AND THE UNITED-KINGDOM

    Oct 1, 2018, 00:00

  • PCN362 - UNDERSTANDING PATIENT AND CLINICIAN PERCEPTIONS OF CELL AND GENE THERAPY IN ONCOLOGY USING QUALITATIVE ANALYSES OF SOCIAL MEDIA DATA

    Oct 1, 2018, 00:00

  • PCV54 - ESTIMATED ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN GERMANY, ITALY, AND THE UK

    Oct 1, 2018, 00:00

  • PSY48 - BUDGET IMPACT ANALYSIS OF LOW-DOSE METHOXYFLURANE FOR THE TREATMENT OF MODERATE-TO-SEVERE TRAUMA PAIN IN CONSCIOUS ADULT PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PHP46 - IS EUROPE WAKING UP TO BIOPHARMACEUTICAL INNOVATION? PERSPECTIVES FROM EXPERT APPRAISAL OF RECENT ORPHAN DISEASE THERAPY VALUE ASSESSMENTS AND THEIR SUPPORTING LEGAL / POLICY FRAMEWORKS

    Oct 1, 2018, 00:00

  • PSY121 - RELATIVE VALUE ASSESSMENT OF TREATMENTS FOR RARE DISEASES

    Oct 1, 2018, 00:00

  • PMD113 - COST–UTILITY OF SURGICAL SUTURELESS BIOPROSTHESES VS. TAVI IN AORTIC VALVE REPLACEMENT FOR PATIENTS AT INTERMEDIATE AND HIGH SURGICAL RISK

    Oct 1, 2018, 00:00

  • PCV145 - A SYSTEMATIC LITERATURE REVIEW (SLR) ON HEALTH STATE UTILITIES ASSOCIATED WITH ANGINA AND REVASCULARISATION

    Oct 1, 2018, 00:00

  • PCN331 - PERTUZUMAB RISK SHARING AGREEMENT IN THE PORTUGUESE NHS

    Oct 1, 2018, 00:00

  • PSY222 - HEALTH RELATED QUALITY OF LIFE (HRQOL) IN MULTIPLE MYELOMA (MM) PATIENTS IN BULGARIA

    Oct 1, 2018, 00:00

  • PMH8 - DEPRESSION IS ASSOCIATED WITH CHRONIC DISORDERS IN CHILDREN AND ADOLESCENTS

    Oct 1, 2018, 00:00

  • PMU47 - THE ECONOMIC BURDEN OF OCCUPATIONAL INJURY AMONG FRONTLINE CONSTRUCTION WORKERS IN GHANA

    Oct 1, 2018, 00:00

  • PIN53 - IS THE RECOMBINANT ZOSTER VACCINE ALSO COST-EFFECTIVE FOR THE GERMAN POPULATION ≥50 YEARS OF AGE?

    Oct 1, 2018, 00:00

  • PCN267 - HEALTHCARE UTILIZATION AND ECONOMIC BURDEN ON PATIENTS WITH BLADDER CANCER IN THE US DEPARTMENT OF DEFENSE POPULATION

    Oct 1, 2018, 00:00

  • PCN222 - TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILISATION (HCRU) IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) IN CANADA AND EUROPE

    Oct 1, 2018, 00:00

  • PCN349 - CAN WE APPLY THE UTILITY PREDICTION MATHEMATICAL MODEL FOR RECURRENT METASTATIC BREAST CANCER TO JAPANESE PATIENTS?

    Oct 1, 2018, 00:00

  • PHP194 - THE EMA CLINICAL DATA WEBSITE- A CONCEPTUAL EXPLORATORY APPROACH TO BENCHMARK CLINICAL DEVELOPMENT INDICATORS IN MARKETING AUTHORIZATIONS

    Oct 1, 2018, 00:00

  • PHP180 - ACCESS AND VALUE OF HEALTHCARE INNOVATION IN LATIN AMERICA

    Oct 1, 2018, 00:00

  • PMU32 - ORPHAN DRUG PRICES IN EUROPE- IMPACT OF EXTERNAL REFERENCE PRICING

    Oct 1, 2018, 00:00

  • PMD112 - COST-UTILITY ANALYSIS OF VAGUS NERVE STIMULATION(VNS) FOR CHILDREN WITH INTRACTABLE EPILEPSY IN TAIWAN

    Oct 1, 2018, 00:00

  • PGI50 - HAPPY TOMORROW BUT GLOOMING ELDERLY? SELF-ESTIMATION OF FUTURE HEALTH IN CROHN’S DISEASE

    Oct 1, 2018, 00:00

  • PCV14 - TREATMENT EFFECT OF PHARMACEUTICAL CARE FOR HYPERTENSIVE PATIENTS IN PRIMARY CARE- A SYSTEMATIC REVIEW AND META-ANALYSES

    Oct 1, 2018, 00:00

  • PHP233 - DIVERGENCE IN UK HTA RECOMMENDATIONS- NOT ALWAYS A NICE OUTCOME

    Oct 1, 2018, 00:00

  • PCV156 - CORRELATION OF THE DISEASE-SPECIFIC CSS/NYHA CLASSIFICATION WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN CORONARY ARTERY DISEASE PATIENTS

    Oct 1, 2018, 00:00

  • PDB82 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM (DPP) 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER QALY CALCULATIONS MAY REVIVE ITS METFORMIN CONCLUSIONS

    Oct 1, 2018, 00:00

  • PND71 - A COST MINIMISATION ANALYSIS OF CLADRIBINE TABLETS VERSUS ALTERNATIVE HIGH EFFICACY TREATMENTS FOR RELAPSING MULTIPLE SCLEROSIS (RMS) IN THE UNIED KINGDOM.

    Oct 1, 2018, 00:00

  • PSS54 - ETHICAL VALIDATION PROCESS FOR VIDEO RECORDED QUALITATIVE INTERVIEWS- EXPERIENCE FROM A RESEARCH PROJECT IN DERMATOLOGY IN FRANCE AND CANADA

    Oct 1, 2018, 00:00

  • PSS25 - COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)

    Oct 1, 2018, 00:00

  • PMU60 - IS TRANSPARENCY IN SLOVAK HTA EFFICIENT ENOUGHT? COMPARING PHARMACOECONOMICS METHODOLOGIES USED IN PRICING REIMBURSEMENT APPLICATIONS FOR INNOVATIVE THERAPIES TOWARDS REQUIREMENTS DEFINED BY THE LAW

    Oct 1, 2018, 00:00

  • PHP59 - MOVING FROM THE REGULATOR TO THE PAYER AND PRESCRIBER - HOW PHARMA CAN WORK BETTER TO EFFECTIVELY MANAGE EMERGING CHALLENGES TO THE COMMERCIAL SUCCESS OF INNOVATIVE NEW THERAPIES

    Oct 1, 2018, 00:00

  • PMS7 - LOSS OF QALYS ASSOCIATED WITH BIOSIMILAR DISCONTINUATION DUE TO NOCEBO EFFECT

    Oct 1, 2018, 00:00

  • PCV22 - LIPID-LOWERING DRUG PRESCRIPTIONS IN A GROUP OF COLOMBIAN PATIENTS.

    Oct 1, 2018, 00:00

  • PSY196 - THE ECONOMIC BURDEN AND IMPACT ON QUALITY OF LIFE OF HERPES ZOSTER AND POSTHERPETIC NEURALGIA IN INDIVIDUALS AGED 50 YEARS OR OLDER IN ITALY

    Oct 1, 2018, 00:00

  • PSY61 - BARIATRIC SURGERY AND COSTS ASSOCIATED WITH HEALTHCARE USE AT TWO YEARS' FOLLOW-UP

    Oct 1, 2018, 00:00

  • PND45 - CAREGIVER NEED ACROSS STAGES OF ALZHEIMER’S

    Oct 1, 2018, 00:00

  • PRM224 - ARE POTENTIALLY AVOIDABLE HOSPITALIZATIONS EXPLAINED BY PRIMARY CARE? BEWARE OF SPATIAL HETEROGENEITY.

    Oct 1, 2018, 00:00

  • PSY144 - DRUGS INVOLVED IN LAWSUITS FILED AGAINST THE UNIFIED HEALTH SYSTEM (SUS) IN SÃO PAULO - BRAZIL, IN 2017

    Oct 1, 2018, 00:00

  • PIN65 - BUDGET IMPACT ANALYSIS OF THE FIXED DOSE COMBINATION PHOSPHAZIDE/LAMIVUDINE ANTIRETROVIRAL DRUG FOR HIV TREATMENT IN RUSSA

    Oct 1, 2018, 00:00

  • PCP60 - EVOLVING STRATEGIES FOR GENERATING, SYNTHESIZING, AND VISUALIZING REAL WORLD EVIDENCE IN RARE DISEASES

    Oct 1, 2018, 00:00

  • PMU94 - DEVELOPMENT OF JAPANESE PREFERENCE WEIGHT FOR THE ADULT SOCIAL CARE OUTCOMES TOOLKIT (ASCOT) SCT4

    Oct 1, 2018, 00:00

  • PHP83 - THE IMPACT OF THE NEW INNOVATIVE ALGORITHM IN ITALY

    Oct 1, 2018, 00:00

  • PSY1 - RISK OF LIVER ENZYME ELEVATION IN AUTOIMMUNE PATIENTS WITH DIFFERENT HEPATITIS B VIRUS INFECTION STATUS RECEIVING BIOLOGIC AGENTS

    Oct 1, 2018, 00:00

  • PND78 - SOCIO-ECONOMIC IMPACT OF DRAVET SYNDROME IN GERMANY- A REAL-WORLD STUDY

    Oct 1, 2018, 00:00

  • PIH47 - SELF-MEDICATION PRACTICE IN PRIMARY DYSMENORRHEA AMONG MEDICAL AND PHARMACY STUDENTS IN UNAIZAH – KSA - A CROSS-SECTIONAL QUESTIONNAIRE STUDY

    Oct 1, 2018, 00:00

  • PSY162 - EVALUATION OF DIRECT COSTS AND TREATMENT PATTERNS ASSOCIATED WITH THE MANAGEMENT OF NEUROPATHIC PAIN IN COLOMBIA

    Oct 1, 2018, 00:00

  • PIN125 - A SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITIES FOR HPV-RELATED DISEASES

    Oct 1, 2018, 00:00

  • PCN33 - SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES FOR FIRST-LINE TREATMENTS IN ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PSS30 - COST EFFECTIVENESS OF DIMETHYL FUMARATE (DMF) IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS- A UK PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCV99 - ANALYSIS OF MEAN AGE OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION IN HUNGARY, 2010-2017

    Oct 1, 2018, 00:00

  • PIH18 - DIRECT COST OF UNINTENDED PREGNANCIES IN JAPAN- ESTIMATING POTENTIAL IMPACTS WITH INCREASED USE OF MODERN CONTRACEPTIVES

    Oct 1, 2018, 00:00

  • PIH15 - PREVALENCE OF DIAGNOSED UTERINE FIBROIDS AND ENDOMETRIOSIS IN THE US- DATA FROM A NATIONALLY REPRESENTATIVE POPULATION-BASED SURVEY

    Oct 1, 2018, 00:00

  • PRM8 - CLINICAL APPLICATION AND USAGE OF PATIENT REPORTED OUTCOME MEASURES IN AN ORTHOPAEDIC OUTPATIENT SETTING

    Oct 1, 2018, 00:00

  • PSY174 - IS PHARMACOKINETIC DRIVEN THERAPY OF POTENTIAL BENEFIT IN HEMOPHILIA?

    Oct 1, 2018, 00:00

  • PSY35 - SYSTEMATIC LITERATURE REVIEW ON THE WORLDWIDE EPIDEMIOLOGY OF METHYLMALONIC ACIDEMIA WITH A FOCUS ON METHYLMALONYL-COA MUTASE DEFICIENCY

    Oct 1, 2018, 00:00

  • PMD33 - BUDGET IMPACT ANALYSIS OF A DUAL-LAYER STENT RETRIEVER (DLSR) FOR THE TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE (AIS) IN ENGLAND

    Oct 1, 2018, 00:00

  • PND116 - A THREE MONTH INTERIM ANALYSIS OF FINGOLIMOD TREATMENT ADHERENCE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK- THE PATIENT REPORTED OUTCOMES WITH FINGOLIMOD IN LOCAL EXPERIENCE (PROFILE) STUDY

    Oct 1, 2018, 00:00

  • PCN66 - LANDMARK ANALYSES IN ONCOLOGY – SEEING BEYOND THE SURFACE AND PROPOSING A STRUCTURED DATA ANALYSIS CHECKLIST

    Oct 1, 2018, 00:00

  • PRS27 - ECONOMIC BURDEN OF IDIOPATHIC PULMONARY FIBROSIS (IPF) IN CHINA

    Oct 1, 2018, 00:00

  • PHP114 - THE ERRATIC AND LONG ACCESS JOURNEY OF ORPHAN DRUGS FROM EUROPE TO PORTUGAL

    Oct 1, 2018, 00:00

  • PRM190 - METHODS USED TO VALUE HEALTH RELATED QUALITY IN A SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES IN HEART FAILURE

    Oct 1, 2018, 00:00

  • PHP131 - WHAT USE IS DISTRIBUTED LEDGER TECHNOLOGY IN REAL-WORLD PRACTICE? - A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCV120 - INDICATORS OF PRESCRIPTIVE APPROPRIATENESS AS A LEVER FOR PHARMACEUTICAL SUSTAINABILITY - THE CASE OF LOW MOLECULAR WEIGHT HEPARINS

    Oct 1, 2018, 00:00

  • PRS7 - PROPHYLACTIC VERSUS SELECTIVE USE OF SURFACTANT IN PRETERM INFANTS IN KOREA - KOREAN NEONATAL NETWORK

    Oct 1, 2018, 00:00

  • PRM45 - DIRECT DATA WITHOUT DUPLICATION OF EFFORT- EXPERIENCE OF OBTAINING ELECTRONIC ROUTINE RESOURCE USE DATA DIRECTLY FROM HOSPITALS FROM THE UPSTREAM RCT.

    Oct 1, 2018, 00:00

  • PMS42 - SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSS15 - BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE

    Oct 1, 2018, 00:00

  • PHP244 - BRIDGING THE GAP- ENSURING FAIR ASSESSMENT OF ORPHAN TREATMENTS BY HEALTH TECHNOLOGY ASSESSMENTS IN ENGLAND

    Oct 1, 2018, 00:00

  • PMU74 - POTENTIAL COST SAVINGS BY PREVENTION OF ADVERSE DRUG EVENTS WITH A NOVEL MEDICATION REVIEW PROGRAM

    Oct 1, 2018, 00:00

  • PCP48 - STABILITY OF RESULTS IN SIMULATION BASED HEALTH ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • PND55 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY- COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY ...

    Oct 1, 2018, 00:00

  • PIH44 - OLDER PEOPLE WITH LONG TERM CONDITIONS USING TECHNOLOGIES SUPPORTING HOME BASED CARE- PATTERNS OF RESOURCE USE, COSTS AND HEALTH RELATED QUALITY OF LIFE

    Oct 1, 2018, 00:00

  • PDB40 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF TYPE 2 DIABETES ENHANCEMENT PATIENT’S OUTCOMES AT COUNTRIES WITH HIGH INCIDENCE OF DIABETES EGYPT CASE

    Oct 1, 2018, 00:00

  • PIN111 - IMPACT OF VARIATION IN INFLUENZA VACCINATION SCHEDULES AND DECISION-MAKING CRITERIA ON PATIENT OUTCOMES IN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • Estimating a Dutch Value Set for the Pediatric Preference-Based CHU9D Using a Discrete Choice Experiment with Duration

    Oct 1, 2018, 00:00

  • PSY76 - ECONOMIC BURDEN OF DISEASES RELATED TO OVERWEIGHT AND OBESITY IN COLOMBIA

    Oct 1, 2018, 00:00

  • PCV88 - PHARMACOECONOMICS OF ALIROCUMAB IN TREATMENT OF HYPERCHOLESTEROLEMIA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PSY182 - A TARGETED REVIEW OF HAEMATOLOGY SINGLE TECHNOLOGY APPRAISALS (STAS) BY NICE SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)

    Oct 1, 2018, 00:00

  • PMH44 - CANADIAN ECONOMIC IMPACT OF IMPROVED WORKPLACE PRODUCTIVITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH VORTIOXETINE

    Oct 1, 2018, 00:00

  • PMH34 - A CONCEPTUAL ECONOMIC MODEL FOR DIGITAL INTERVENTIONS IN SERIOUS MENTAL ILLNESS

    Oct 1, 2018, 00:00

  • PIN73 - ECONOMIC BURDEN OF HIV/AIDS AMONG ELDERLY MEDICARE BENEFICIARIES POST MEDICARE PART D

    Oct 1, 2018, 00:00

  • PRS18 - POTENTIAL SAVINGS ACHIEVED THROUGH SWITCHING COPD PATIENTS FROM ICS-CONTAINING REGIMENS TO LAMA+LABA- A SPANISH PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PCV47 - PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS

    Oct 1, 2018, 00:00

  • PCP57 - LIQUID BIOPSIES IN EARLY DETECTION OF BREAST CANCER, METASTATIC PROGRESSION AND THERAPY OUTCOMES- OPPORTUNITIES AND CHALLENGES FOR THE PERSPECTIVE OF PATIENTS, PROVIDERS AND PAYERS

    Oct 1, 2018, 00:00

  • PMH63 - ACCESS TO ANTI-DEPRESSANT THERAPIES IN ENGLAND- IS THERE A POSTCODE LOTTERY?

    Oct 1, 2018, 00:00

  • PRS42 - COST-EFFECTIVENESS OF INDACATEROL/GLYCOPYRRONIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN BRAZIL

    Oct 1, 2018, 00:00

  • PIN61 - COST-EFFECTIVENESS OF ONCE-DAILY DARUNAVIR CONTAINING SINGLE-TABLET REGIMEN (D/C/F/TAF) COMPARED WITH OTHER MULTI-TABLET REGIMENS CONTAINING BOOSTED PROTEASE INHIBITORS (BPIS)

    Oct 1, 2018, 00:00

  • PCN318 - CONDUCTING AND REPORTING INDIRECT TREATMENT COMPARISONS- A CRITICAL APPRAISAL OF ONCOLOGY TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PDB22 - CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS REACHING A HIGH DAILY DOSE OF IDEGLIRA SIX MONTHS AFTER INITIATION IN A REAL-WORLD SETTING

    Oct 1, 2018, 00:00

  • PMD181 - PATIENT PREFERENCE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INHALERS- A DISCRETE CHOICE EXPERIMENT (DCE) IN FRANCE

    Oct 1, 2018, 00:00

  • PDB86 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA

    Oct 1, 2018, 00:00

  • PDB21 - COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS IN TYPE II DIABETES DERIVED FROM AN OVERVIEW OF 55 SYSTEMATIC REVIEWS

    Oct 1, 2018, 00:00

  • PMU116 - PATIENT-REPORTED OUTCOMES IN A PILOT RANDOMIZED TRIAL OF GENOME SEQUENCING

    Oct 1, 2018, 00:00

  • PMS13 - REAL-WORLD TREATMENT OF PATIENTS WITH OSTEOPOROSIS IN GERMANY- PREVALENCE AND INCIDENCE OF PATIENTS WITH OSTEOPOROSIS AT INCREASED FRACTURE RISK

    Oct 1, 2018, 00:00

  • PHP93 - THE IMPACT OF SUPPLY CHAIN MARGINS AND VAT ON THE PRICES OF MEDICINES IN BULGARIA AND GREECE

    Oct 1, 2018, 00:00

  • PIN108 - HUMAN PAPILLOMAVIRUS VACCINATION UPTAKE BARRIERS AMONG ADOLESCENTS AND THEIR PARENTS IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PND40 - COST OF HEALTHCARE RESOURCE USE BY PATIENTS WITH MULTIPLE SCLEROSIS IN FRANCE ACCORDING TO DISEASE SEVERITY

    Oct 1, 2018, 00:00

  • PMH32 - ECONOMIC IMPACT OF OPIOID DEPENDENCE IN GERMANY- A COST OF ILLNESS STUDY FOCUSSING ON PATIENTS IN OPIOID MAINTENANCE TREATMENT

    Oct 1, 2018, 00:00

  • PGI10 - COMPARATIVE EFFECTIVENESS OF PAN-GENOTYPIC THERAPIES FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION IN BULGARIA

    Oct 1, 2018, 00:00

  • PIN101 - ACUTE GASTROENTERITIS HOSPITALIZATIONS- EXPLORING SPATIO-TEMPORAL PATTERNS AND SELF-FINANCED ROTAVIRUS VACCINATION EFFECT

    Oct 1, 2018, 00:00

  • PCN378 - MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPS

    Oct 1, 2018, 00:00

  • PHP118 - IMPACT OF COHORT TEMPORARY AUTHORISATION FOR USE ON PRICE IN FRANCE

    Oct 1, 2018, 00:00

  • PUK8 - EVALUATION OF PRESCRIBING PRACTICES AND DRUG-RELATED PROBLEMS IN CHRONIC KIDNEY DISEASE PATIENTS- A PROSPECTIVE OBSERVATIONAL STUDY

    Oct 1, 2018, 00:00

  • PCV30 - REAL WORLD EVIDENCE OF THE RISK OF STROKE OR SYSTEMIC EMBOLISM IN CHRONIC KIDNEY DISEASE PATIENTS WITH ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PIH2 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION FOLLOWING HYSTERECTOMY

    Oct 1, 2018, 00:00

  • PDB100 - STUDY ON AWARENESS REGARDING NEWER TRENDS IN DIABETES MEDICATION MANAGEMENT

    Oct 1, 2018, 00:00

  • PHP96 - TIME EFFICIENCY IN THE REGULATORY DECISION-MAKING PROCESS OF ORPHAN DRUGS

    Oct 1, 2018, 00:00

  • PRM7 - THE USE OF NATURAL LANGUAGE PROCESSING TO ASSESS PATIENTS WITH BLEEDS IN THEIR NOTES IN THE OPTUM EHR DATABASE

    Oct 1, 2018, 00:00

  • PMD131 - MEDICAL IMAGING EQUIPMENT IN ITALY- STATE OF ART OF INSTALLED BASE AND RENEWAL STRATEGIES

    Oct 1, 2018, 00:00

  • PCN212 - PREVALENCE OF CANCER AMONG WOMEN IN A TERTIARY TEACHING HOSPITAL IN LAGOS SOUTHWEST NIGERIA- A PHARMACOEPIDEMIOLOGICAL AND EVIDENCE BASED SURVEY

    Oct 1, 2018, 00:00

  • PCN244 - REAL-WORLD EVIDENCE ON THE UTILISATION OF REGORAFENIB IN IRELAND

    Oct 1, 2018, 00:00

  • PUK35 - WORK PRODUCTIVITY AND EQ-5D UTILITY OF PATIENTS WITH CHRONIC KIDNEY DISEASE BY ANEMIA SEVERITY- POOLED RESULTS FROM THREE CROSS-SECTIONAL INTERNATIONAL SURVEYS

    Oct 1, 2018, 00:00

  • PCN185 - COST-EFFECTIVENESS OF NIVOLUMAB IN SECOND-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA IN ADULTS AFTER FAILURE OF PRIOR PLATINUM-CONTAINING THERAPY IN GREECE

    Oct 1, 2018, 00:00

  • PSY207 - IS LATE NIGHT EATING LINKED TO CHILDHOOD OBESITY? A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • CV1 - A COST-EFFECTIVENESS ANALYSIS OF MULITI-GENE PHARMACOGENETIC TESTING IN ACUTE CORONARY SYNDROME PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

    Oct 1, 2018, 00:00

  • PND10 - GENIUS RWE STUDY (FINGOLIMOD REAL WORLD EVIDENCE ITALIAN MULTICENTER OBSERVATIONAL STUDY IN MULTIPLE SCLEROSIS)PRELIMINARY RESULTS

    Oct 1, 2018, 00:00

  • PND62 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS IN THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMS33 - CATEGORISING PATIENTS WITH RHEUMATOID ARTHRITIS USING TRAJECTORIES OF DISEASE ACTIVITY SCORE IN HUNGARY

    Oct 1, 2018, 00:00

  • PRM197 - RESPONDER DEFINITION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS)-29 V2 AMONG PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA- AN EMPIRICAL APPROACH

    Oct 1, 2018, 00:00

  • PND36 - COSTS OF MULTIPLE SCLEROSIS IN DENMARK- A REGISTER BASED STUDY

    Oct 1, 2018, 00:00

  • PHP266 - MANAGED ACCESS PROGRAMS- A FIRST STEP FOR UK HTA?

    Oct 1, 2018, 00:00

  • PMS43 - AN ECONOMIC VALUE FRAMEWORK TO ASSESS THE COST EFFECTIVENESS OF FRACTURE PREVENTION TREATMENTS IN PATIENTS WITH OSTEOPOROSIS AT IMMINENT RISK OF FRACTURE

    Oct 1, 2018, 00:00

  • PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM- HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALS

    Oct 1, 2018, 00:00

  • PSY203 - DESCRIPTIVE EPIDEMIOLOGY OF OBESITY IN A REAL WORLD POPULATION OF ADULTS IN THE UNITED STATES- 2010 - 2017

    Oct 1, 2018, 00:00

  • PRM234 - HAZARD RATIO ESTIMATION USING DIFFERENT METHODS- AN IMPACT ASSESSMENT

    Oct 1, 2018, 00:00

  • PCN268 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) FOLLOWING INITIAL PLATINUM THERAPY IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PCN231 - PRICING, AVAILABILITY, AFFORDABILITY, PRICE COMPONENTS OF ESSENTIAL ANTICANCER MEDICINES IN ADDIS ABABA, ETHIOPIA

    Oct 1, 2018, 00:00

  • PIH3 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION AFTER CAESAREAN SECTION

    Oct 1, 2018, 00:00

  • PRM65 - DIFFERENT COST EFFECTIVENESS MODELS USED FOR ECONOMIC EVALUATION IN MODERATE TO SEVERE PAINFUL DIABETIC NEUROPATHY OR POST-HERPETIC NEURALGIA

    Oct 1, 2018, 00:00
  • «
  • 61
  • 62
  • 63
  • 64 (current)
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • »